Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group None., (2024), Diabet Med, 41

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

Empagliflozin in Patients with Chronic Kidney Disease.

The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127

LDL-cholesterol reduction in chronic kidney disease: options beyond statins.

Goonasekera MA. et al, (2020), Curr Opin Nephrol Hypertens, 29, 480 - 488

The importance of positive need fulfillment: Evidence from a sample of war-affected Sri Lankans.

Jayawickreme E. et al, (2019), Am J Orthopsychiatry, 89, 159 - 169

Longitudinally extensive spinal cord infarction in CADASIL.

Hinze S. et al, (2015), Pract Neurol, 15, 60 - 62